← Back to Search

Exercise + Liraglutide for Metabolic Syndrome (ZQL008 Trial)

Phase 4
Recruiting
Led By Zhenqi Liu, MD
Research Sponsored by University of Virginia
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Meet 3 of 5 National Cholesterol Education Program Adult Treatment Panel III Metabolic Syndrome criteria: Increased waist circumference (≥102 cm in men; ≥88 cm in women), Elevated triglycerides (≥150 mg/dl), Reduced HDL-cholesterol (<40mg/dl in men, <50 mg/dl in women), High blood pressure (≥130 mmHg systolic or ≥85mmHg diastolic), Elevated fasting glucose (≥100 mg/dl)
Male or female ≥21 and ≤60 years old
Must not have
A diagnosis of any type of diabetes or history of diabetes medication use
A prior use of Liraglutide
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24weeks
Awards & highlights
No Placebo-Only Group
Pivotal Trial
Drug Has Already Been Approved

Summary

This trial is studying whether exercise, liraglutide, or both can improve cardiac and skeletal muscle function in people with Metabolic Syndrome.

Who is the study for?
Adults aged 21-60 with Metabolic Syndrome, not currently very active, and have a stable weight (BMI between 25-35) can join. They must meet at least three criteria like large waist size, high triglycerides or blood sugar, low HDL cholesterol, or high blood pressure. Those on certain stable medications may also qualify.
What is being tested?
The study is testing the effects of exercise alone, the drug Liraglutide alone, and both combined on heart and muscle blood flow and insulin function in people with Metabolic Syndrome over 24 weeks. Participants will be randomly placed into one of four groups including a control group.
What are the potential side effects?
Possible side effects from Liraglutide include digestive issues like nausea or diarrhea; allergic reactions; headache; dizziness; increased heart rate. Exercise might cause muscle soreness or injury if not done properly.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I meet at least 3 of the 5 criteria for Metabolic Syndrome.
Select...
I am between 21 and 60 years old.
Select...
I am between 21 and 60 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have diabetes or have taken medication for it.
Select...
I have previously used Liraglutide.
Select...
I am currently smoking or quit smoking less than 5 years ago.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Microvascular Blood Volume - change from baseline
Secondary study objectives
Augmentation Index - change from baseline
Flow Mediated Dilation
Insulin Sensitivity - change from baseline
+2 more

Side effects data

From 2017 Phase 4 trial • 100 Patients • NCT02014740
29%
nausea
100%
80%
60%
40%
20%
0%
Study treatment Arm
Liraglutide
Metformin

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.

Trial Design

3Treatment groups
Experimental Treatment
Group I: Liraglutide AloneExperimental Treatment1 Intervention
24 weeks of treatment
Group II: Exercise AloneExperimental Treatment1 Intervention
24 weeks of treatment
Group III: Exercise + LiraglutideExperimental Treatment1 Intervention
24 weeks f treatment
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Liraglutide
2013
Completed Phase 4
~2680

Find a Location

Who is running the clinical trial?

University of VirginiaLead Sponsor
785 Previous Clinical Trials
1,316,366 Total Patients Enrolled
5 Trials studying Metabolic Syndrome
478 Patients Enrolled for Metabolic Syndrome
National Institutes of Health (NIH)NIH
2,838 Previous Clinical Trials
8,171,868 Total Patients Enrolled
12 Trials studying Metabolic Syndrome
2,147 Patients Enrolled for Metabolic Syndrome
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
2,463 Previous Clinical Trials
4,337,323 Total Patients Enrolled
35 Trials studying Metabolic Syndrome
2,860 Patients Enrolled for Metabolic Syndrome
Zhenqi Liu, MDPrincipal Investigator - Division of Endocrinology and Metabolism, University of Virginia
UVA-HealthSouth Rehabilitation Hospital, University of Virginia Medical Center
Hunan Medical University (Medical School)
University Of Va Medical Center (Residency)
3 Previous Clinical Trials
96 Total Patients Enrolled

Media Library

Exercise training Clinical Trial Eligibility Overview. Trial Name: NCT04575844 — Phase 4
Metabolic Syndrome Patient Testimony for trial: Trial Name: NCT04575844 — Phase 4
~5 spots leftby Apr 2025